The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant
chemoradiotherapy in microsatellite stable (MSS) locally advanced rectal cancer (LARC). A
total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by
capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3
cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of
adjuvant chemotherapy of XELOX. The tumor response grade, adverse effects and long-term
prognosis will be analyzed.